Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Christina E. Hoeve"'
Autor:
Gerco den Hartog, Stijn P. Andeweg, Christina E. Hoeve, Gaby Smits, Bettie Voordouw, Dirk Eggink, Mirjam J. Knol, Robert S. van Binnendijk
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Immunity induced by vaccination and infection, referred to as hybrid immunity, provides better protection against SARS-CoV-2 infections compared to immunity induced by vaccinations alone. To assess the development of hybrid immunity we inves
Externí odkaz:
https://doaj.org/article/6ca9bd240db74a499af470bcf0273d1f
Autor:
Brechje de Gier, Anne J. Huiberts, Christina E. Hoeve, Gerco den Hartog, Henri van Werkhoven, Rob van Binnendijk, Susan J. M. Hahné, Hester E. de Melker, Susan van den Hof, Mirjam J. Knol
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-7 (2023)
Abstract An increasing proportion of the population has acquired immunity through COVID-19 vaccination and previous SARS-CoV-2 infection, i.e., hybrid immunity, possibly affecting the risk of new infection. We aim to estimate the protective effect of
Externí odkaz:
https://doaj.org/article/88c2a47cb73b465283b1375a636466cc
Autor:
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, Hester E. de Melker, Susan J.M. Hahné, Gerco den Hartog, Diederick E. Grobbee, Janneke H.H.M. van de Wijgert, Susan van den Hof, Mirjam J. Knol
Publikováno v:
International Journal of Infectious Diseases, Vol 133, Iss , Pp 36-42 (2023)
Objectives: We estimated vaccine effectiveness (VE) of primary and booster vaccinations against SARS-CoV-2 infection overall and in four risk groups defined by age and medical risk condition during the Delta and Omicron BA.1/BA.2 periods. Methods: VA
Externí odkaz:
https://doaj.org/article/cc5ca02290674c1cb7fffc7534999ab4
Autor:
Diederick E Grobbee, Gerco den Hartog, Hester E de Melker, Susan van den Hof, Marjolein N Kooijman, Anne J Huiberts, Christina E Hoeve, Susan JM Hahné, Rob van Binnendijk, Janneke HHM van de Wijgert, Mirjam J Knol
Publikováno v:
BMJ Open, Vol 14, Iss 10 (2024)
Purpose VAccine Study COVID-19 (VASCO) is a cohort study with a 5-year follow-up that was initiated when COVID-19 vaccination was introduced in the Netherlands. The primary objective is to estimate real-world vaccine effectiveness (VE) of COVID-19 va
Externí odkaz:
https://doaj.org/article/60a37bacff594edcb3b9232fd68edb2b
Autor:
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, Hester E. de Melker, Susan J.M. Hahné, Gerco den Hartog, Diederick E. Grobbee, Janneke H.H.M. van de Wijgert, Susan van den Hof, Mirjam J. Knol
IntroductionMonitoring of COVID-19 vaccine effectiveness (VE) is needed to inform vaccine policy. We estimated VE of primary vaccination, and first and second booster vaccination, against SARS-CoV-2 infection overall, and in four risk groups defined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::079bf987dffda268a0eb16f71c41a730
http://hdl.handle.net/10029/626674
http://hdl.handle.net/10029/626674
Autor:
Christina E Hoeve, Brechje de Gier, Anne J Huiberts, Hester E de Melker, Susan J M Hahné, Susan van den Hof, Mirjam J Knol
Publikováno v:
The Journal of Infectious Diseases.
Background We aimed to estimate vaccine effectiveness against infection (VE-infection) and against further transmission (VE-infectiousness) in a household setting during Delta and Omicron. Knowing these effects can aid policy makers in deciding which
Autor:
Anne J Huiberts, Brechje de Gier, Christina E Hoeve, Hester E de Melker, Susan JM Hahné, Gerco den Hartog, Janneke HHM van de Wijgert, Susan van den Hof, Mirjam J Knol
Publikováno v:
Eurosurveillance. 28
We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1
Autor:
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, Hester E. de Melker, Susan J.M. Hahné, Gerco den Hartog, Janneke H.H.M. van de Wijgert, Susan van den Hof, Mirjam J. Knol
We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent Original/Omicron BA.1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ce80f631c815f1798ba977303c1d469
https://doi.org/10.1101/2023.02.08.23285643
https://doi.org/10.1101/2023.02.08.23285643
Autor:
Christina E. Hoeve, Brechje de Gier, Anne J. Huiberts, Hester E. de Melker, Susan J.M. Hahné, Susan van den Hof, Mirjam J. Knol
IntroductionWe aimed to estimate vaccine effectiveness against infection (VE- infection) and infectiousness (VE-infectiousness) in a household setting during Delta and Omicron. Knowing these effects can aid policy makers in deciding which groups to p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fd6be305602bf14653e570385b05f52
https://doi.org/10.1101/2023.01.10.23284386
https://doi.org/10.1101/2023.01.10.23284386
Autor:
Peter G. M. Mol, Christina E. Hoeve, Esther de Vries, Sabine M. J. M. Straus, Miriam C. J. M. Sturkenboom
Publikováno v:
Drug Safety, 44, 73-82. ADIS INT LTD
Drug Safety, 44(1), 73-82. Adis
Drug Safety
Drug Safety, 44(1), 73-82. Adis
Drug Safety
Introduction When serious medication errors (ME) are identified, communication to the field may be necessary. In the EU, communication of serious safety issues, such as medication errors associated with adverse drug reactions, is done through direct